In a groundbreaking endeavor that bridges neurology, immunology, and sleep medicine, a team of Yale-led researchers has officially launched a clinical trial to investigate whether the anti-inflammatory drug adalimumab can delay or entirely prevent the onset of Parkinson’s disease. The study targets individuals diagnosed with rapid eye movement sleep behavior disorder (RBD), a distinct parasomnia strongly associated with an elevated risk of developing the debilitating neurodegenerative condition.
Spearheaded by Jesse Cedarbaum, MD, professor of neurology, and David Hafler, MD, the William S. and Lois Stiles Edgerly Professor of Neurology at the Yale School of Medicine, the new trial represents a historic milestone. It is the first clinical study of its kind designed to test whether a targeted pharmacological intervention can halt or slow the progression of Parkinson’s disease before the emergence of any traditional motor symptoms.
The rationale behind the trial rests on a crucial temporal window. The pathological hallmarks of Parkinson’s disease—most notably the abnormal clumping of a protein called alpha-synuclein—manifest in the human body decades before a patient ever experiences tremors, rigidity, or slowed movement. Among the earliest clinical warning signs of this underlying cascade is rapid eye movement sleep behavior disorder, a condition where individuals physically and sometimes violently act out their dreams because the normal biological paralysis mechanism of REM sleep fails to function. Clinical statistics show that up to 90% of idiopathic or isolated RBD cases eventually progress into Parkinson’s disease or related synucleinopathies, such as dementia with Lewy bodies.
This years-long latency period creates a vital opportunity for early medical intervention. Recent investigations conducted by scientists at the Yale School of Medicine suggest that neuroinflammation within the central nervous system plays a critical and active role in driving this disease trajectory. By deploying adalimumab—a widely prescribed biologic medication currently used to manage chronic inflammatory and autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis—the research team hopes to intercept the pathological process at its earliest, most manageable stage.
The clinical trial, formally titled "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder" or "PRISMS," has successfully enrolled its first participant. The multi-center trial is actively recruiting individuals between the ages of 50 and 80 who present with confirmed RBD across 15 specialized academic medical centers spanning the United States and Canada.
"This is the first clinical trial of its kind to use an immunologically-based approach to try to slow the progression of Parkinson’s disease," Cedarbaum notes, emphasizing the novel paradigm shift the study represents for neurodegenerative research.
What is REM Sleep Behavior Disorder?
To understand the significance of the PRISMS study, clinicians emphasize the unique nature of rapid eye movement sleep. REM sleep is the distinct phase of the human sleep cycle characterized by vivid dreaming, during which the eyes move rapidly beneath closed eyelids. In a healthy nervous system, the brain engages an active protective mechanism that effectively paralyzes the body from the neck down, ensuring that physical movements do not accompany internal dream scenarios.
When this dream paralysis mechanism breaks down, RBD develops. Patients suffering from the disorder frequently put themselves and their bed partners at risk of physical injury by thrashing, punching, or falling out of bed. Clinical observations have even documented patients engaging in complex, coordinated activities during sleep, such as drinking a cup of coffee or smoking a cigarette.
While certain triggers, including specific antidepressant medications, can induce secondary forms of RBD, many patients develop the condition spontaneously. This isolated or idiopathic RBD carries a profound prognosis. According to Cedarbaum, individuals who present to clinical specialists with idiopathic RBD convert to Parkinson’s disease or a related neurodegenerative disorder at a rate of approximately 6% per year, with the transition unfolding across a 15- to 20-year timeline.
Emerging scientific consensus points to the gastrointestinal tract as a frequent starting point for the pathological cascade of Parkinson’s disease. All healthy human nerve cells contain alpha-synuclein, a functional protein, but post-mortem analyses of brains from Parkinson’s patients consistently reveal dense, toxic aggregates known as Lewy bodies. Researchers have similarly identified aberrant clumps of synuclein within the enteric nervous system of the gut. These protein aggregates can subsequently propagate upward toward the central nervous system via neural pathways, most notably the vagus nerve connecting the stomach and intestines to the brainstem. Alternatively, pathology can originate in the olfactory bulb, explaining why many future Parkinson’s patients experience an early loss of their sense of smell.
Once alpha-synuclein reaches the brainstem, it progressively spreads from one neuron to the next. Some of the earliest neural populations affected are those responsible for governing sleep-related muscle paralysis, giving rise to the characteristic symptoms of RBD. As the proteinaceous aggregates continue their ascent, they eventually infiltrate the substantia nigra, a critical midbrain structure situated within the basal ganglia. The substantia nigra is responsible for producing dopamine, a vital neurotransmitter that acts as a signaling chemical for the basal ganglia network, which regulates voluntary movement.
"Your brain has all these programs for making movements, and the basal ganglia is like the gearbox," Cedarbaum explains. "Dopamine acts like oil. And when alpha synuclein damages the cells in the substantia nigra, they no longer make their dopamine oil, and movement gets slow, and sticky, and tremulous."
While standard therapeutic agents like levodopa successfully replenish dopamine levels and temporarily suppress the motor symptoms of Parkinson’s disease, they do not alter the underlying trajectory of alpha-synuclein as it continues to propagate upward through the brain, eventually impairing cognitive centers and causing dementia over decades. Because the detection of RBD serves as an early clinical alarm bell indicating that this multi-decade pathological process is already underway, researchers view it as an ideal juncture for preventative intervention.
Inflammation and Parkinson’s Disease
The accumulation and spread of alpha-synuclein represent only one dimension of the disease mechanism. Cedarbaum, whose career has focused heavily on finding ways to protect dopamine-producing neurons from dying, was originally preparing for retirement when he was approached by Hafler, an internationally renowned authority on multiple sclerosis. Hafler’s pioneering work has fundamentally transformed the therapeutic landscape for autoimmune conditions, and he hypothesized that similar immunological principles might apply to neurodegenerative disorders like Parkinson’s disease.
Recognizing parallels between the early presentation of RBD and the initial stages of multiple sclerosis, Hafler and Cedarbaum secured a grant in 2021 from the Aligning Science Across Parkinson’s (ASAP) network. The research team performed diagnostic spinal taps on a large cohort comprising participants with RBD, established Parkinson’s disease, and concurrent manifestations of both conditions, comparing their biomarker profiles against healthy control subjects and multiple sclerosis patients.
The resulting biochemical analyses revealed elevated white blood cell counts—a classic indicator of active inflammation—within the cerebrospinal fluid of participants diagnosed with RBD. Interestingly, this marked inflammatory signature was absent in patients who had already advanced to diagnosed Parkinson’s disease. Hafler notes that this trajectory mirrors the natural history of multiple sclerosis. In the early autoimmune phase of multiple sclerosis, white blood cells are readily detectable in the spinal fluid, whereas advanced disease stages transition away from pure inflammation toward progressive neurodegeneration.
Further cellular interrogation using single-cell RNA sequencing pinpointed specific immune cells within the spinal fluid that exhibited upregulated inflammatory gene expression. These cells functioned as receptors for tumor necrosis factor (TNF), a powerful signaling protein known to drive a spectrum of autoimmune conditions, including rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
"This gave us additional evidence that, at least in the early stages of Parkinson’s disease, inflammation, and, in particular, things related to TNF might be important," Cedarbaum observes.
Intriguingly, epidemiological data demonstrates that individuals suffering from chronic inflammatory conditions like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis face a heightened statistical risk of developing Parkinson’s disease, mirroring the elevated vulnerability seen in RBD patients. However, clinical observations indicate that patients treated with adalimumab—a monoclonal antibody designed to bind to circulating TNF and neutralize its inflammatory effects—experience a normalized risk profile comparable to that of healthy individuals. This intersection prompted researchers to evaluate whether adalimumab could directly mitigate the neuroinflammatory processes contributing to Parkinson’s pathogenesis.
"We know that in the early stages of Parkinson’s disease, there’s a lot of inflammation," says Ronald Postuma, MD, professor of neurology at McGill University and principal investigator for the PRISMS study in Canada. "And so, if you tamp down the immune system, potentially you could prevent bystander damage—the immune cells attacking cells that they should not be attacking."
What is the PRISMS Study?
The PRISMS clinical trial is a collaborative undertaking coordinated by the Center for Health Technology at the University of Rochester. The trial relies on 14 participating academic centers across the United States, along with one site in Canada, all operating within the Parkinson Study Group, an established consortium that has successfully conducted over 100 clinical trials for movement disorders over the past four decades.
To qualify for enrollment, prospective candidates must undergo a polysomnography, or comprehensive sleep study, to secure a definitive diagnosis of RBD. To maximize the certainty that alpha-synuclein aggregation underlies the patient’s condition without requiring invasive procedures like spinal taps or skin biopsies at the screening stage, investigators will evaluate candidates for hyposmia, or a diminished sense of smell. Clinical validation studies have demonstrated that individuals presenting with both RBD and olfactory loss possess at least a 90% probability of harboring underlying alpha-synuclein pathology. Consequently, meeting both criteria is mandatory for trial eligibility.
Once enrolled, participants are randomly assigned to self-administer subcutaneous injections of either adalimumab or a matching placebo once every two weeks over a total duration of two years. Throughout the study, participants will return to their respective clinical sites approximately nine times for comprehensive health assessments, cognitive evaluations, and standardized motor testing. Blood draws will be routinely performed to analyze immune cell dynamics and monitor for Parkinson’s-related protein biomarkers. Additionally, a subset of participants will undergo periodic lumbar punctures to track longitudinal changes in cerebrospinal fluid constituents, including alpha-synuclein aggregation.
The trial protocol also incorporates advanced neuroimaging. Participants will undergo three specialized brain scans annually. Two of these imaging sessions, including a structural and functional magnetic resonance imaging protocol, will assess the functional integrity of the brain’s dopaminergic system. A third imaging modality measures regional cerebral glucose metabolism using a safe, trace amount of radioactive sugar. Because the brains of individuals developing Parkinson’s disease exhibit characteristic metabolic abnormalities years prior to the onset of motor symptoms, these imaging biomarkers will serve as a primary gauge of therapeutic efficacy.
"If our drug prevents worsening of this pattern, or the loss of dopamine signal, we will have a hint that the drug is working," Cedarbaum explains.
Investigators acknowledge that adalimumab carries known pharmacological side effects, including an increased susceptibility to certain infections such as tuberculosis and hepatitis, as well as a slightly elevated risk for specific malignancies and demyelinating neurological symptoms resembling multiple sclerosis. Trial coordinators will maintain rigorous safety monitoring protocols throughout the study lifecycle.
While currently available therapies successfully manage the motor manifestations of Parkinson’s disease, they are unable to alter its fundamental progression. By shifting the clinical focus toward early immunological intervention before motor disability appears, the research team hopes to fundamentally alter the medical management of neurodegenerative disorders.
"In the multiple sclerosis world, if we treat the disease very early, it is 98% effective in stopping the disease," Hafler notes. "We hope to achieve something similar with Parkinson’s disease. It’s all about recognizing a disease and treating it early."
The investigative team hopes that the PRISMS study will serve as a catalyst for expanded research exploring immunologically targeted therapeutics for Parkinson’s disease and other neurodegenerative conditions, paving the way for subsequent trials evaluating additional pharmacological candidates.
"Finding anything that will slow down the progression to the serious stages of the disease would really be a game changer," Postuma concludes.
